Table 2.
Echocardiographic evaluation of systolic and diastolic function of infarcted SHR after treatment with LASSBio-294
| Functional indices | SHR-Sham + DMSO | SHR-MI + DMSO | SHR-MI + LASSBio-294 (10 mg.kg−1) | SHR-MI + LASSBio-294 (20 mg.kg−1) |
|---|---|---|---|---|
| EF (%) | 78.33±4.58 | 51.01±4.37** | 72.43±3.71&& | 75.84±4.37&& |
| FS (%) | 43.44±2.98 | 26.65±3.96* | 40.81±2.72 | 42.29±4.40& |
| E/A | 1.48±0.09 | 0.99±0.04* | 1.35±0.07& | 1.43±0.13&& |
Notes:
*
P<0.05 compared to SHR-Sham;
**
P<0.01 compared to SHR-Sham;
&&
P<0.01 compared to SHR-MI;
&
P<0.05 compared to SHR-IM. n=6. Measurements performed 4 weeks after surgery. SHR-Sham treated with DMSO and SHR-MI treated with DMSO or LASSBio-294 orally, 10 and 20 mg.kg−1 diluted in DMSO. Data are expressed as mean ± SEM.
Abbreviations: DMSO, dimethyl sulfoxide; E/A, early transmitral filling velocity/late transmitral filling velocity; EF, ejection fraction; FS, fractional shortening; SHR, spontaneously hypertensive rats; LASSBio-294, 3,4-methylenedioxybenzoyl-2-thienylhydrazone; MI, myocardial infarction.